Martin Capital Advisors LLP Acquires 133 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Martin Capital Advisors LLP lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,169 shares of the financial services provider’s stock after acquiring an additional 133 shares during the period. iShares Biotechnology ETF accounts for approximately 1.4% of Martin Capital Advisors LLP’s holdings, making the stock its 21st biggest holding. Martin Capital Advisors LLP’s holdings in iShares Biotechnology ETF were worth $1,918,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in shares of iShares Biotechnology ETF by 25.7% during the 1st quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock worth $282,038,000 after purchasing an additional 420,053 shares during the period. Main Management ETF Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 2.6% during the second quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after buying an additional 14,535 shares during the last quarter. Global Assets Advisory LLC purchased a new stake in shares of iShares Biotechnology ETF in the first quarter worth approximately $66,059,000. Raymond James Financial Services Advisors Inc. lifted its stake in shares of iShares Biotechnology ETF by 24.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after acquiring an additional 42,822 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in iShares Biotechnology ETF by 5.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 198,709 shares of the financial services provider’s stock valued at $27,267,000 after acquiring an additional 10,033 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ IBB opened at $145.59 on Monday. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $150.57. The company’s 50-day moving average price is $145.12 and its 200-day moving average price is $139.38.

iShares Biotechnology ETF Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.